secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001213900-26-019617
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TARA-002 shows 68% CR at 6 months in BCG-unresponsive NMIBC; no Grade 3+ TRAEs
------------------------------------------------------------------------------

- BCG-Unresponsive cohort: CR rate 68.2% at 6 months (15/22), 33.3% at 12 months (5/15); 61.5% re-induction conversion.
- BCG-Naïve cohort: CR rate 66.7% at 6 months (18/27), 57.9% at 12 months (11/19); 66.7% re-induction conversion.
- No Grade 3 or greater treatment-related adverse events; no discontinuations due to TRAEs; common TRAEs were dysuria (14%), bladder spasm (9%).
- Enrollment completion of BCG-Unresponsive registrational cohort expected 2H 2026; ADVANCED-3 registrational trial for BCG-Naïve to start 2H 2026.
- Data presented at ASCO GU 2026; company hosted conference call on Feb 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/0001213900-26-019617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026019617/ea0277972-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-019617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer